Last Updated on August 20, 2025 by The Health Master
Lalit Kr Goel
Panchkula, Haryana — The pharmaceutical landscape in Haryana is buzzing with optimism following the promotion of Lalit Kr Goel to the esteemed position of State Drugs Controller-cum-Licensing Authority, Food and Drugs (FDA) Haryana.
The pharma industry, which is actively working to establish Haryana as a dominant manufacturing hub in North India, believes Goel’s leadership will be a game-changer.
Lalit Kr Goel’s Blueprint for a Better Future for the stakeholders
Lalit Kr Goel has outlined a series of key plans to create a healthier environment for pharmaceutical businesses.
These include:
- Streamlining the approvals and renewals with clear guidelines to significantly reduce processing delays for transparent and efficient licensing.
- Fair, uniform, and consistent enforcement of regulations to ensure the safe and effective delivery of drugs to the people of the region.
- In-time guidance and support with prompt responses to technical queries and clarifications on day-to-day operational issues.
- Combating Counterfeit Drugs:
In an important move to safeguard public health, Lalit Kr Goel has announced a bold plan to form an interstate coordination committee to combat the threat of counterfeit, fake, and spurious drugs.
This initiative will bring together drug controllers from five northern states—Delhi, Haryana, Himachal Pradesh, Uttarakhand, and Punjab—to create a unified and robust strategy.
The committee’s primary goal is to enable joint actions, share intelligence, and establish a seamless information-sharing network to dismantle drug rackets that operate across state borders.
This collaborative effort is seen as an important step towards creating a more robust enforcement mechanism and protecting the public from the dangers of substandard, fake, and spurious drugs.
Goel has indicated that the first meeting is planned for next month to formalize this collaboration, marking a CRUCIAL step forward in regional drug regulation.
A Leader with a Proven Track Record
Narender Ahooja, the former SDC of Haryana, also lauded Goel, calling him a highly knowledgeable expert on drug acts and rules.
Ahooja highlighted Goel’s hands-on approach, where he provides helpful guidance to industries, especially MSMEs.
He expressed confidence that under Goel’s leadership, the FDA Haryana will reach new heights, and the industry will thrive.
Vikas Pruthi, the general secretary of the Haryana Pharmaceutical Manufacturers Association (HPMA), expressed the industry’s profound confidence in Goel.
He highlighted Goel’s unwavering dedication, integrity, and deep understanding of regulatory affairs as qualities that have already inspired the sector.
This appointment comes at a time when the state’s pharmaceutical industry is poised for substantial expansion.
The association strongly believes that Goel’s tenure will usher in a transformative period marked by increased efficiency and unprecedented transparency.
Praise for Lalit Kr Goel’s appointment is not limited to manufacturers.
Sharad Mehrotra, president of the Gurugram Chemists and Druggists Association (GCDA), described Goel as a disciplined, integrous, and humble individual who consistently seeks to learn.
Mehrotra praised his exceptional and straightforward approach, noting that he prefers to guide and educate rather than punish.
Satish Vij, president of the Haryana Drug Dealers Association (HDDA), added that Goel’s vast experience and knowledge, particularly on topics like the NDPS Act and Schedule M, make him an ideal leader.
Vij is hopeful that Goel’s work will significantly improve coordination between the trade and the department.
Q: What is the purpose of the interstate committee?
A: The interstate committee, comprising drug controllers from five northern states (Delhi, Haryana, Himachal Pradesh, Uttarakhand, and Punjab), aims to create a unified strategy to combat counterfeit, fake, and spurious drugs through joint actions, intelligence sharing, and a robust enforcement mechanism.
NPPA fixed retail price of 37 formulations: August 2025
NPPA fixed Ceiling price of 4 scheduled formulations: August 2025
Drug Imports: New Online System for Dual Use NOC launched
FSSAI: Food Labelling and Display – Chapter-20
USFDA inspection: At Torrent Pharma with zero observations at Vizag
Govt. appoints Adnl. DGHS as the Compounding Authority
USFDA inspection: At Granules India arm with 1 observation
Amendment: Know About the Cosmetics (Amendment) Rules, 2025
USFDA inspection: At Senores Pharma arm with 3 observations
